Annual CFF
$14.78 M
-$19.94 M-57.43%
December 31, 2022
Summary
- As of March 9, 2025, ARDS annual cash flow from financing activities is $14.78 million, with the most recent change of -$19.94 million (-57.43%) on December 31, 2022.
- During the last 3 years, ARDS annual CFF has risen by +$9.79 million (+196.05%).
- ARDS annual CFF is now -57.43% below its all-time high of $34.72 million, reached on December 31, 2021.
Performance
ARDS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$999.00 K
-$2.03 M-67.01%
September 30, 2023
Summary
- As of March 9, 2025, ARDS quarterly cash flow from financing activities is $999.00 thousand, with the most recent change of -$2.03 million (-67.01%) on September 30, 2023.
- Over the past year, ARDS quarterly CFF has dropped by -$2.03 million (-67.01%).
- ARDS quarterly CFF is now -96.02% below its all-time high of $25.08 million, reached on September 30, 2018.
Performance
ARDS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$15.32 M
+$1.55 M+11.28%
September 30, 2023
Summary
- As of March 9, 2025, ARDS TTM cash flow from financing activities is $15.32 million, with the most recent change of +$1.55 million (+11.28%) on September 30, 2023.
- Over the past year, ARDS TTM CFF has increased by +$1.55 million (+11.28%).
- ARDS TTM CFF is now -59.38% below its all-time high of $37.72 million, reached on September 30, 2021.
Performance
ARDS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ARDS Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -57.4% | -67.0% | +11.3% |
3 y3 years | +196.1% | +100.0% | +1951.1% |
5 y5 years | -29.8% | -79.9% | +206.9% |
ARDS Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -57.4% | at low | -90.9% | +280.3% | -55.9% | +76.1% |
5 y | 5-year | -57.4% | +196.1% | -95.7% | +280.3% | -59.4% | +1951.1% |
alltime | all time | -57.4% | +196.1% | -96.0% | +280.3% | -59.4% | +1951.1% |
Aridis Pharmaceuticals Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2023 | - | $999.00 K(-67.0%) | $15.32 M(+11.3%) |
Jun 2023 | - | $3.03 M(+1051.3%) | $13.77 M(+29.9%) |
Mar 2023 | - | $263.00 K(-97.6%) | $10.60 M(-28.3%) |
Dec 2022 | $14.78 M(-57.4%) | $11.03 M(-2091.3%) | $14.78 M(+69.9%) |
Sep 2022 | - | -$554.00 K(+298.6%) | $8.70 M(-73.3%) |
Jun 2022 | - | -$139.00 K(-103.1%) | $32.59 M(+0.0%) |
Mar 2022 | - | $4.44 M(-10.3%) | $32.58 M(-6.2%) |
Dec 2021 | $34.72 M(+300.1%) | $4.95 M(-78.8%) | $34.72 M(-7.9%) |
Sep 2021 | - | $23.34 M(<-9900.0%) | $37.72 M(+162.3%) |
Jun 2021 | - | -$149.00 K(-102.3%) | $14.38 M(-5.7%) |
Mar 2021 | - | $6.58 M(-17.2%) | $15.25 M(+75.7%) |
Dec 2020 | $8.68 M | $7.95 M(>+9900.0%) | $8.68 M(+1061.7%) |
Sep 2020 | - | $0.00(-100.0%) | $747.00 K(-86.9%) |
Jun 2020 | - | $715.00 K(+5007.1%) | $5.71 M(+14.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2020 | - | $14.00 K(-22.2%) | $5.00 M(+0.1%) |
Dec 2019 | $4.99 M(-80.1%) | $18.00 K(-99.6%) | $4.99 M(+0.2%) |
Sep 2019 | - | $4.97 M(>+9900.0%) | $4.99 M(-80.1%) |
Jun 2019 | - | $0.00(-100.0%) | $25.10 M(0.0%) |
Mar 2019 | - | $8000.00(-20.0%) | $25.10 M(+0.0%) |
Dec 2018 | $25.09 M(+19.1%) | $10.00 K(-100.0%) | $25.09 M(+0.0%) |
Sep 2018 | - | $25.08 M(>+9900.0%) | $25.08 M(+124.6%) |
Jun 2018 | - | $0.00(0.0%) | $11.16 M(-32.6%) |
Mar 2018 | - | $0.00(0.0%) | $16.56 M(-21.3%) |
Dec 2017 | $21.06 M(-17.4%) | $0.00(-100.0%) | $21.06 M(0.0%) |
Sep 2017 | - | $11.16 M(+106.7%) | $21.06 M(+112.8%) |
Jun 2017 | - | $5.40 M(+20.1%) | $9.90 M(+120.1%) |
Mar 2017 | - | $4.50 M | $4.50 M |
Dec 2016 | $25.50 M | - | - |
FAQ
- What is Aridis Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Aridis Pharmaceuticals?
- What is Aridis Pharmaceuticals annual CFF year-on-year change?
- What is Aridis Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aridis Pharmaceuticals?
- What is Aridis Pharmaceuticals quarterly CFF year-on-year change?
- What is Aridis Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aridis Pharmaceuticals?
- What is Aridis Pharmaceuticals TTM CFF year-on-year change?
What is Aridis Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ARDS is $14.78 M
What is the all time high annual CFF for Aridis Pharmaceuticals?
Aridis Pharmaceuticals all-time high annual cash flow from financing activities is $34.72 M
What is Aridis Pharmaceuticals annual CFF year-on-year change?
Over the past year, ARDS annual cash flow from financing activities has changed by -$19.94 M (-57.43%)
What is Aridis Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ARDS is $999.00 K
What is the all time high quarterly CFF for Aridis Pharmaceuticals?
Aridis Pharmaceuticals all-time high quarterly cash flow from financing activities is $25.08 M
What is Aridis Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ARDS quarterly cash flow from financing activities has changed by -$2.03 M (-67.01%)
What is Aridis Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ARDS is $15.32 M
What is the all time high TTM CFF for Aridis Pharmaceuticals?
Aridis Pharmaceuticals all-time high TTM cash flow from financing activities is $37.72 M
What is Aridis Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ARDS TTM cash flow from financing activities has changed by +$1.55 M (+11.28%)